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INTRODUCTION
All wounds progress through a series of predictable 
stages before achieving complete wound closure.1 Howev-
er, some wounds stall in the healing process and become 
chronic.2 The etiology of chronic nonhealing wounds is 
complex, but many occur as a result of increased bacterial 
bioburden and the formation of biofilm.3,4 Biofilm repre-
sents a stage of the normal growth cycle of bacteria, dur-
ing which they are in a protected state.
A recent meta-analysis calculated the prevalence of 
biofilms in chronic wounds at 78.2%, and in some stud-
ies, the rates are even higher.5–9 Elevated bioburden and 
biofilm can also be found in acute wounds, such as burns 
and skin tears with tissue loss, with biofilm present in ap-
proximately 6% of acute wounds.8,10,11
Biofilm can impair wound healing by producing an ele-
vated, but ineffective, inflammatory state.12 The formation 
of a biofilm results in an increase in proteolytic enzymes 
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Background: Biofilm can impair wound healing by maintaining an elevated, but 
ineffective, inflammatory state. This article describes interim results from the pro-
spective RESPOND postmarketing registry evaluating the use of a native type 1, 
porcine collagen matrix with the embedded antimicrobial polyhexamethylene bi-
guanide (PCMP) in the management of chronic wounds.
Methods: Adults ≥18 years of age with ≥1 appropriate wound were eligible for in-
clusion. Data that were final on January 26, 2018 were included in this analysis. At 
week 0, wounds were cleaned, debrided, and prepared as necessary and PCMP was 
applied, with a dressing to fix it in place. Patients received standard wound care 
plus PCMP weekly, up to 24 weeks, at the investigator’s discretion. At each visit, 
wounds were assessed for area and quality of granulation tissue.
Results: Most common wound types (N = 63) were venous ulcers (28.6%), trauma 
and lacerations (22.2%), postsurgical open wounds (15.9%), pressure injuries 
(12.7%), and diabetic ulcers (9.5%). Median baseline wound area was 6.5 cm2; 
mean wound duration at baseline was 4 months. Of the 63 wounds, 43 (68.3%) 
achieved complete wound closure, 41 of 43 (95.3%) closed after PCMP treatment, 
and 2 of 43 (4.7%) after bridging to other modalities and surgical closure. Twelve 
out of 63 wounds were bridged to other modalities after PCMP treatment. Mean 
time to closure for PCMP wounds was 5.0 weeks.
Conclusions: PCMP appears to be a useful adjunct for treating various wound 
types. PCMP use should be considered when managing chronic or acute wounds. 
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that manipulate the host response by inducing proinflam-
matory cytokines and proteases.13 This creates a cascade of 
changes that induce chronic inflammation and turn acute 
wounds into chronic wounds. Because of the extracellular 
polymeric substance secreted by the bacterial species in a 
biofilm, neutrophils and macrophages are unable to pen-
etrate the biofilm and are rendered ineffective.
Debridement is an essential step in disrupting biofilm, 
but it is not sufficient by itself to reduce and maintain low-
er bacterial counts in wounds.14–16 A reduction in bacte-
rial counts for up to 48 hours after debridement has been 
noted.17 After debridement, the use of topical antimicrobi-
als is a treatment strategy that can be effective in reducing 
and maintaining lower bacterial counts and preventing 
biofilm reformation.18,19
Polyhexamethylene biguanide (PHMB) is a cationic 
topical antimicrobial that strongly binds to bacterial 
cell walls and membranes, disrupting the transport, 
biosynthesis, and catabolic functions of the bacte-
ria.20,21 PHMB possesses broad antimicrobial activity 
against gram-positive and gram-negative bacteria, and 
plaque- and biofilm-forming bacteria.21 Furthermore, 
PHMB binds to biofilm matrix components, and the 
local PHMB concentration increases during applica-
tion to cause an increasingly toxic environment for 
the bacteria.22 Multidrug efflux pumps or acquired re-
sistance to an antimicrobial compound developed by 
the bacteria do not appear to affect PHMB efficacy.20,21 
PHMB shows good biocompatibility and little to no tox-
icity or systemic uptake when applied on intact skin or 
wounds.21,23 PHMB also shows activity against a variety 
of other microorganisms including yeast and fungi.24,25 
PHMB has been effective in wound care of leg ulcers 
and prevention of central-line–associated bloodstream 
infections.26,27
Collagen dressings are frequently used in wound care, 
owing to their properties that encourage cellular migra-
tion and new tissue formation, and to their ease of han-
dling and conformability.28,29 Matrices made of native 
collagen can be beneficial in promoting wound healing.28 
The native collagen matrix possesses many properties that 
make it attractive for wound management. The network 
provides a scaffold for constructive tissue remodeling, al-
lowing fibroblasts and keratinocytes to attach, proliferate, 
and migrate.30,31 Native collagen matrices possess strength 
and flexibility, as well as growth factors that are released 
during matrix degradation.31,32 Another role that collagen 
matrices play is to act as a substrate to decrease the high 
levels of elastase and matrix metalloproteinases that are 
often present in chronic wounds.29,33
A recent development in wound healing is a skin sub-
stitute construct of a native type 1, porcine-derived colla-
gen matrix with a 0.1% PHMB coating (porcine collagen 
matrix with PHMB, further referenced as PCMP). PCMP 
is a US Food and Drug Administration Class II medical de-
vice, 510(k)-cleared #K051647, and intended for the man-
agement of wounds. PCMP is supplied dry in sheet form 
and packaged as sterile, sealed single patches.34
PCMP is a native extracellular matrix (ECM) made 
from small intestine submucosa (SIS) that retains the na-
tive structure of collagen, with the addition of PHMB. SIS 
grafts provide structure for vascular and cellular ingrowth. 
Grafts with intact collagen structure are more resistant to 
enzymatic degradation and obtain better cell adhesion 
compared with those made from denatured collagen. The 
addition of PHMB to the SIS graft (or native ECM) pro-
vides all of the above attributes and antimicrobial action 
against a broad spectrum of bacteria.
The RESPOND Registry (Real-World Effectiveness 
Study of PuraPly AM on Wounds) is a postmarketing, 
open-label, prospective, observational multicenter study 
(ClinicalTrials.gov Registration #NCT03286452; regis-
tered September 18, 2017) examining the use of PCMP in 
treating wounds in real-world clinical settings. The aim of 
this study is to determine the impact of PCMP on wound 
environment and management of chronic wounds (eg, 
increase in healthy granulation tissue, decrease in bio-
burden, and decrease in amount of exudate) for up to 24 
weeks.
This article reports an interim analysis of 63 patients 
in the RESPOND registry treated with PCMP (PuraPly An-
timicrobial, Organogenesis Inc., Canton, Mass.) who had 
completed their participation and whose data were final as 
of January 26, 2018. Over 300 patients are enrolled in the 
registry to date.
METHODS
The registry protocol was reviewed and approved by 
Sterling Institutional Review Board (registration num-
ber IRB00001790) and was conducted in accordance 
with current International Council for Harmonisation 
Good Clinical Practice guidelines and 21 CFR Parts 11, 
50, 56, and applicable regulations. All patients provid-
ed their written informed consent to participate in the 
registry.
One target wound per patient was identified for study 
inclusion and was followed for up to 24 weeks. The choice 
to initiate treatment of the wound with PCMP was made by 
the Investigator, independent of and before the patient’s 
decision to participate in the RESPOND registry. Patients 
received standard wound treatment and clinical assess-
ments appropriate for their wound type, as determined by 
the Investigator.
Patients
Adults ≥18 years of age with at least 1 appropriate 
wound (partial and full-thickness wounds of various eti-
ologies including pressure injuries, venous ulcers, diabetic 
ulcers, chronic vascular ulcers, open surgical wounds, or 
trauma wounds with tissue loss) were eligible for inclu-
sion. The term “pressure injury” is interchangeable with 
“pressure ulcer” and describes localized damage to the 
skin and underlying soft tissue, usually over a bony promi-
nence or related to a medical or other device. Individuals 
were excluded from participating if they were receiving 
concurrent treatment with other topical antimicrobials 
or skin substitute products, if they had received previ-
ous PCMP treatment for the study wound, or if they had 
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a third-degree burn or a known sensitivity to any of the 
PCMP materials.
Objectives
The primary objective was to assess the effectiveness of 
PCMP in real-world clinical settings, as measured by per-
cent reduction in wound area, time to complete wound 
closure, and improvement in wound bed condition (as 
indicated by an increase in healthy granulation tissue, re-
duction in biofilm, reduction in amount of exudate, and 
readiness for application of advanced therapy).
Procedures
Eligible and enrolled patients received their initial 
PCMP application at the baseline visit. Baseline assess-
ments included patient demographics, medical and 
surgical history, target wound etiology, duration and re-
currence information, and previous surgical interventions 
and treatments (ie, offloading, compression, skin substi-
tutes, hyperbaric oxygen, and negative pressure wound 
therapy).
Before the first application, the target wound was 
cleansed, debrided as necessary, and measurements (sur-
face area and depth) were taken. PCMP was applied and 
the patient returned to the clinic weekly for subsequent 
PCMP applications and wound care assessments. The in-
vestigator determined the frequency and type of assess-
ments and standard wound care for each patient, but the 
clear majority of patients received a weekly wound surgical 
and/or sharp debridement, followed by wound brushing, 
cleansing with normal saline, and PCMP reapplication. 
Data were collected at each patient visit during which 
PCMP was applied, and at postapplication follow-up visits 
as appropriate for up to 24 weeks.
The registry protocol did not specify how the investiga-
tor was to perform normal wound care using PCMP. An 
example of a typical regimen at 2 of the study sites is as 
follows: Wounds were cleansed and debrided at the initial 
visit. After initial debridement, cultures would be taken 
if the patient’s wound was boggy, purulent, or cellulitic. 
PCMP was applied unless gross purulence was noted. After 
wound bed preparation, PCMP was applied, wetted with 
normal saline, affixed with Steri-Strips, and subsequently 
hydrogel and a nonstick layer were applied. Each PCMP 
sheet could remain on the study wound for 1 week. Dress-
ings applied over PCMP were left to the treating physician; 
for example, a hydrogel and a low evaporative dressing 
(Adaptic or Xeroform) were often applied over PCMP. Pa-
tients would be placed in compression wraps if indicated 
(eg, in cases of venous leg ulcers). PCMP would then be 
reapplied weekly. After 4–6 weeks, the decision was made 
to switch to a cellular graft if there was no significant re-
duction in wound/ulcer size, or to continue with PCMP if 
the wound was reducing in size.
At one of the authors’ institutions, patients entering 
the study with lower extremity wounds and lower ex-
tremity edema received a venous duplex assessment for 
venous insufficiency and reflux, and all patients enter-
ing the study with lower extremity wounds with nonpal-
pable pulses had, at minimum, an ankle-brachial index 
assessment within the first week of enrollment. Patients 
with venous ulcers received endovenous procedures to 
correct venous insufficiency, and patients with arterial 
insufficiency received arterial interventions to augment 
wound healing, all within the first 2 weeks of entering 
the study. The use of vascular intervention in patients 
with venous or arterial insufficiency at enrollment is in 
concordance with clinical practice guidelines for the 
management of peripheral artery disease.35,36 In these pa-
tients, and all others in this study, PCMP was used as an 
adjunct to standard of care.
Assessments
At each follow-up clinic visit, wound characteristics, 
size (area and depth), and quality of granulation tissue 
were assessed and recorded. PCMP was applied weekly at 
the investigator’s discretion, and photographs were taken 
of the wound before and after PCMP application and de-
bridement, if performed, and upon healing, if it occurred.
Any pertinent concomitant treatments, procedures, 
and medications, and target wound-related adverse events 
were assessed and recorded.
Statistical Analysis
Data from patients who received PCMP and completed 
the study by the interim analysis cutoff date (January 26, 
2018) were analyzed. Descriptive statistics (mean, SD) and 
percentage wound closure at 4, 8, and 12 weeks and at 
the end of study were calculated with Microsoft Excel 2016 
(version 16.0.9330.2124).
RESULTS
A total of 63 patients completed the study by the data 
cutoff. The mean (SD) age of patients was 76.1 (13.8) 
years and 32 (50.8%) were male (Table 1). At baseline, 
18 of 63 (28.6%) of wounds were venous ulcers, 14 of 63 
(22.2%) were trauma and lacerations (category includes 
skin tears [n = 2], and wound dehiscence [n = 1] 10 of 63 
(15.9%) were postsurgical open wounds, 8 of 63 (12.7%) 
were pressure injuries, 6 of 63 (9.5%) were diabetic ul-
cers, 2 of 63 (3.2%) were chronic vascular wounds, and 
5 of 63 (7.9%) were another type, including tick bite 
(n = 1) and vasculitis (n = 1) (data were unavailable for 
the 3 remaining wounds marked as “other”). The me-
dian (interquartile range) baseline wound area was 6.5 
(11.8) cm2. The mean baseline wound duration was 4 
months. The 63 wounds in this interim analysis received 
an average of 4 PCMP applications each. Some patients 
received adjunct therapy during their registry participa-
tion.
Of the 63 wounds, 43 (68.3%) achieved complete 
wound closure by the interim analysis cutoff date (Fig. 1). 
Of the 43 wounds that achieved complete wound closure, 
41 of 43 (95.3%) closed after PCMP treatment and 2 of 
43 (4.7%) after bridging to other modalities and surgical 
closure. Overall, 12 of 63 wounds were bridged to other 
modalities after PCMP treatment. Two examples of wound 
healing are shown in Figure 3.
PRS Global Open • 2019
4
At week 4, 33.3% (21 of 63) of wounds had complete-
ly healed, and at week 8, 50.8% had completely healed. 
Wound closure by wound type at Weeks 4, 8, and 12 is 
shown in Figure 2. The mean and median time to wound 
closure was 5.0 weeks for those that closed after PCMP 
treatment. In the wounds that did not achieve complete 
closure, 14 decreased in area from baseline to the end 
of the study by an average of 54.1%, and 5 increased in 
size (data on the lesion area at the end of the study time-
point were missing for 1 patient). The 2 chronic vascular 
wounds did not heal. The 5 patients who had enlarged 
wounds ranged in age from 69 to 91 years, and the wounds 
had been present for 1–4 months (wound duration was 
unavailable for 1 of these 5 patients). The 5 wounds that 
increased in size were venous ulcers (n = 2), pressure ul-
cer (n = 1), postsurgery (n = 1), and post-Moh’s surgery 
(n = 1). Reasons or other factors given for increase in 
wound size were: congestive heart failure, renal failure, 
and chronic obstructive pulmonary disease led to death 
within 3 weeks (venous ulcer); worsening infection with 
contributing factors of polymyalgia rheumatica (treated 
with low-dose prednisone) and thrombocytosis (treated 
with hydroxyurea) (venous ulcer); myocardial infarction, 
peripheral vascular disease, and bladder cancer resulted 
in transfer to hospice 2 weeks into the study (postsurgi-
cal wound); after 4 weeks of treatment, patient dropped 
out of registry and transferred to different facility (post-
Moh’s surgery), and noncompliance (pressure ulcer). 
There were 2 deaths during the study (1 due to natural 
causes; 1 due to exacerbations of chronic obstructive pul-
monary disease). There were 5 registry discontinuations 
before healing or before reaching the end of the study 
(2 transfer to hospice; 1 Investigator decision; 2 lost to 
follow-up).
Two adverse events of worsening infection and wors-
ening of wound appearance were reported during the 
study, both of which were mild and were not attributed to 
PCMP. The patient reporting a worsening infection had 
swabs of the venous leg ulcer that were sent for culture, 
which returned positive. The patient was started on an-
tibiotics and this event was reported as worsening infec-
tion. This patient also showed wound enlargement. The 
patient reporting worsening wound appearance had a 
diabetic foot ulcer that had been present for many years, 
which had healed a few times but continued to reopen. 
The wound was reported as showing a decline during this 
registry enrollment, which was reported as worsening in 
appearance.
Table 1. Demographic and Baseline Characteristics
Characteristic
Interim Analysis Group 
(N = 63)
Mean age, y (SD) 76.1 (13.8)
Sex, n (%)
  Female 31 (49.2)
  Male 32 (50.8)
Race, n (%)
  White 51 (81.0)
  Black 8 (12.7)
  Hispanic 2 (3.2)
  Unknown 2 (3.2)
BMI, kg/m2, mean (SD)a 26.6 (6.6)a
Wound type, n (%)
  Venous ulcer 18 (28.6)
  Trauma and laceration 14 (22.2)
  Postsurgical wound 10 (15.9)
  Pressure injury 8 (12.7)
  Diabetic ulcer 6 (9.5)
  Chronic vascular wound 2 (3.2)
  Other 5 (7.9)
an = 51.
BMI, body mass index.
Fig. 1. Complete wound closure after pCmp treatment at week 12, by baseline wound type.
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DISCUSSION
Results of the interim analysis of the RESPOND Registry 
show that PCMP appeared to positively impact wound heal-
ing in a variety of lesion types. Many wounds (68%) achieved 
complete closure by 12 weeks, and most (90%) had reduced 
in area from baseline. Complete wound closure was achieved 
in an average of 5 weeks, which was less than the mean dura-
tion of the wounds (12 weeks) before PCMP treatment.
Complete wound closure was seen in many wound 
types, including trauma wounds and lacerations with tis-
sue loss, venous ulcers, postsurgical wounds, and pressure 
injuries. Of the wounds that did not achieve complete 
closure in the study period, 2 were chronic vascular ul-
cers, which lack vascularity and tend not to heal regard-
less of treatment modality. PCMP was well tolerated, and 
no treatment-related adverse events were reported in this 
study. Results seen here were similar to an earlier case se-
ries of PCMP in chronic wounds of various etiology.37
The wound closure results may be attributed to the 
synergistic effect of the native collagen matrix, which pro-
vides a structural substrate and environmental conditions 
that support tissue ingrowth and reduce protease activ-
ity, and the PHMB antimicrobial, which inhibits bacterial 
growth. The collagen matrix by itself does not appear to 
possess antimicrobial properties.38
In this study, patients did not show any hypersensitiv-
ity to PCMP components, and the PHMB antimicrobial 
is known to be very biocompatible. PCMP was also used 
in conjunction with other treatments during this study, 
including oral and intravenous antibiotic therapy, and 
hyperbaric oxygen, with no detectable interactions or ad-
verse effects.
As described by the authors representing a study site 
contributing to this interim data set, the use of PCMP had 
a positive influence on the healthcare costs associated 
with treating patients with appropriate wounds. With a 
streamlined application process for PCMP and the rates 
of healing and time to healing seen in the patients treated 
with PCMP, the medical center considered it a beneficial 
management plan.
PCMP was not compared with another treatment or to 
a standard-of-care group in this study, and the final results 
from the full registry enrollment of more than 300 pa-
tients may provide a broader perspective on the outcomes 
following the use of PCMP. In all patients enrolled in this 
registry, PCMP was used as an adjunct to standard of care. 
Wounds represented in this study were likely to be those 
that were amenable to healing without surgery (eg, ulcers 
that were stage 3 or less), and PCMP was useful to aid heal-
ing with these wounds. Skin substitutes, including PCMP, 
are intended to keep patients out of the operating room 
as much as possible and heal as many as possible without 
the need for surgery.
PCMP may be useful for wound management owing 
to its combination of native ECM and PHMB, ease of ap-
plication, long shelf life, and the range of sizes available 
for managing different wound types. The success of the 
wound management strategy seen here demonstrates the 
Fig. 2. Healing trajectory of various wound types. Wound closure rates over time show an increase in the 
percentage of wounds achieving closure from the beginning of the study through Week 12. all wound 
types, except for chronic vascular wounds, exhibited some wound closure throughout the study.
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importance of addressing bioburden, biofilm reformation, 
and high proteolytic activity to improve wound outcomes.
CONCLUSIONS
PCMP appears to be a useful adjunct in the treatment 
of various types of wounds. Its action against biofilm war-
rants further evaluation. It seems that the combined action 
of the PCMP components, native collagen matrix with ad-
dition of PHMB, may result in a faster time to wound clo-
sure than either component could achieve individually. In 
this case, the use of PCMP was associated with substantial 
reduction in wound area after 4 weeks and notable rates 
of wound closure at up to 12 weeks. PCMP use should be 
considered when managing chronic or acute wounds of 
various etiologies. We will await final data to determine if 
Fig. 3. a, a 58-year-old female presented with a large arterial ischemic ulcer to her lower extremity, which had been present for 56 days 
prior to pCmp application. She received treatments including surgical debridement, 40 hyperbaric oxygen therapy treatments, negative 
pressure therapy, and 10 pCmp applications. the clinician’s goal of therapy was to progress the wound to be ready for a split-thickness 
skin graft. the patient was offered a split-thickness skin graft at week 24 but chose not to undergo grafting due to personal reasons, so 
she preferred to continue the existing course of treatment.
B, Wound at Week 6 
C, at week 52 the patient was discharged with 95% epithelialization. the wound was completely healed at 22 months after initial presen-
tation at the wound center. 
D, a 55-year-old female presented with a history of a traumatic wound, which had been present for 1 week. She received surgical debride-
ment and 4 pCmp applications. 
E, Wound at Week 14.
F, Wound was completely healed at 28 weeks after pCmp applications began.
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further study is needed to compare PCMP to other prod-
ucts on the outcomes measured.
Michael A. Bain, MD, MMS
Chair Department of Plastic Surgery and Medical Director
Wound Healing and Hyperbaric Medicine
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